GILD Financial Facts

Net loss attributable to noncontrolling interest: -5M
Selling, general and administrative: 831M
See Full Income Statement

Long-term marketable securities: 19.35B
Additional paid-in capital: 321M
See Full Balance Sheet

Gilead Sciences Inc. (GILD) Earnings

  |   Expand Research on GILD
Next EPS Date 7/30/21 *Est. EPS Growth Rate +23.8% *Last Qtr.
Average EPS % Beat Rate -3.5% Revenue Growth Rate +15.3% *Last Qtr.
Average % Move 1-Wk after EPS +0.8% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
4/29/21 Q121 $2.08$2.09 -$0.01$6.4B$6.74B = Details
2/4/21 Q420 $2.19$2.15 +$0.04$7.42B$7.33B = Details
10/28/20 Q320 $2.11$1.95 +$0.16$6.6B$6.39B Details
7/30/20 Q220 $1.11$1.45 -$0.34$5.1B$5.31B Details
4/30/20 Q120 $1.68$1.57 +$0.11$5.55B$5.45B Details
2/4/20 Q419 $1.30$1.67 -$0.37$5.9B$5.71B Details
10/24/19 Q319 $1.75$1.74 +$0.01$5.6B$5.61B = Details
7/30/19 Q219 $1.82$1.72 +$0.10$5.69B$5.53B = Details